Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modafinil for Cognitive Impairment in Depression
NCT04317001Phase 3Withdrawn
- Sponsor
- Stanford University
- Start
- Dec 2018
- Primary completion
- Nov 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of modafinil in major depressive disorder (MDD), sponsored by Stanford University. Primary endpoint: Depression, Anxiety and Stress Scale at 28 days. Planned start Dec 2018; status: withdrawn.
02
Drugs
modafinil
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04317001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04317001.